Q2 revenue rises 25%; standalone profit after tax rises 40%; bonus record date fixed

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.8%Reaction day

₹1388.90

prior close

₹1319.90

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.3%-9.1% vs market

Pharmaceuticals peers, median of 170sector+0.6%-9.4% vs sector

On the reaction day the stock moved 9.1 pts less than Nifty Smallcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.8

15m

-2.4

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.8+0.3-9.1+0.6-9.4

Next day

-11.4+1.0-12.4+1.1-12.6

-10.3pendingpending-0.1-10.2

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and half-year results for September 2026. Consolidated revenue rose 25.1% to Rs 309.07 crore and profit after tax rose 10.3% to Rs 69.57 crore. Half-year revenue rose 23.3% and profit after tax 18.8%. Standalone Q2 profit after tax rose 40.2%. A Rs 3.28 crore labour-code charge was an exceptional item in March 2026 full-year figures. The 1:1 bonus record date is November 4, 2026. Four committees were reconstituted.

Likely market impact

Revenue helps, but margin compression and slower overall profit growth may temper gains. The bonus may aid liquidity; per-share figures adjust.